Swedbank’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $663M | Buy |
2,634,628
+237,708
| +10% | +$51.1M | 0.57% | 34 |
|
|
2026
Q1 | $521M | Buy |
2,396,920
+444,441
| +23% | +$98.6M | 0.55% | 39 |
|
|
2025
Q4 | $446M | Sell |
1,952,479
-10,981
| -0.6% | -$2.5M | 0.43% | 51 |
|
|
2025
Q3 | $455M | Buy |
1,963,460
+40,781
| +2% | +$8.3M | 0.46% | 46 |
|
|
2025
Q2 | $357M | Sell |
1,922,679
-13,425
| -0.7% | -$2.5M | 0.4% | 57 |
|
|
2025
Q1 | $406M | Sell |
1,936,104
-36,844
| -2% | -$7.16M | 0.54% | 42 |
|
|
2024
Q4 | $351M | Sell |
1,972,948
-174,178
| -8% | -$32M | 0.43% | 47 |
|
|
2024
Q3 | $424M | Buy |
2,147,126
+6,810
| +0.3% | +$1.27M | 0.54% | 38 |
|
|
2024
Q2 | $367M | Buy |
+2,140,316
| New | +$355M | 0.49% | 40 |
|
|
2024
Q1 | – | Sell |
-1,864,496
| Closed | -$289M | – | 576 |
|
|
2023
Q4 | $289M | Buy |
1,864,496
+27,810
| +2% | +$4.05M | 0.47% | 47 |
|
|
2023
Q3 | $274M | Buy |
1,836,686
+58,039
| +3% | +$8.52M | 0.47% | 46 |
|
|
2023
Q2 | $240M | Buy |
1,778,647
+82,144
| +5% | +$12M | 0.41% | 48 |
|
|
2023
Q1 | $270M | Buy |
1,696,503
+57,199
| +3% | +$8.74M | 0.53% | 42 |
|
|
2022
Q4 | $265M | Buy |
1,639,304
+52,177
| +3% | +$8M | 0.58% | 35 |
|
|
2022
Q3 | $213M | Buy |
1,587,127
+265,897
| +20% | +$38.2M | 0.51% | 43 |
|
|
2022
Q2 | $202M | Buy |
1,321,230
+186,615
| +16% | +$28.5M | 0.46% | 50 |
|
|
2022
Q1 | $184M | Buy |
1,134,615
+18,133
| +2% | +$2.63M | 0.34% | 63 |
|
|
2021
Q4 | $152M | Buy |
1,116,482
+35,964
| +3% | +$4.25M | 0.25% | 81 |
|
|
2021
Q3 | $117M | Buy |
1,080,518
+103,794
| +11% | +$11.9M | 0.22% | 100 |
|
|
2021
Q2 | $110M | Buy |
976,724
+71,653
| +8% | +$8.07M | 0.21% | 110 |
|
|
2021
Q1 | $97.9M | Buy |
+905,071
| New | +$96.8M | 0.2% | 116 |
|
|
2019
Q4 | – | Sell |
-859,217
| Closed | -$65.1M | – | 111 |
|
|
2019
Q3 | $65.1M | Buy |
859,217
+6,773
| +0.8% | +$464K | 0.3% | 92 |
|
|
2019
Q2 | $62M | Buy |
852,444
+16,650
| +2% | +$1.31M | 0.28% | 95 |
|
|
2019
Q1 | $67.4M | Sell |
835,794
-180,356
| -18% | -$14.8M | 0.32% | 86 |
|
|
2018
Q4 | $92.6M | Sell |
1,016,150
-122,369
| -11% | -$10.8M | 0.51% | 75 |
|
|
2018
Q3 | $108M | Sell |
1,138,519
-231,200
| -17% | -$21.9M | 0.48% | 72 |
|
|
2018
Q2 | $127M | Sell |
1,369,719
-7,808
| -0.6% | -$763K | 0.63% | 53 |
|
|
2018
Q1 | $130M | Buy |
1,377,527
+24,607
| +2% | +$2.7M | 0.68% | 51 |
|
|
2017
Q4 | $131M | Buy |
+1,352,920
| New | +$128M | 0.71% | 49 |
|
Other funds holding ABBV
ECSS
ATO
GAM
Swedbank's ABBV Position: Q2 2026 in Review
Swedbank increased its AbbVie (ABBV) stake by 9.9% in Q2 2026, buying an estimated $51.1M and bringing the position to 2,634,628 shares worth $663M. The position accounts for 0.57% of the portfolio, ranked #34.
Swedbank first reported a position in ABBV in Q4 2017 and has held it in 29 quarters since. 1,885 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Swedbank held 2,634,628 shares of AbbVie worth $663M as of Q2 2026.
- Swedbank bought 237,708 AbbVie shares in Q2 2026, an estimated $51.1M.
- AbbVie made up 0.57% of Swedbank's portfolio in Q2 2026, its #34 holding.
- Swedbank first reported a position in AbbVie in Q4 2017 and has held it in 29 quarters since.
- 1,885 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Swedbank's 13F filing for Q2 2026, filed 15 Jul 2026.